Patient recruitment for clinical trials in the biopharma industry is often a challenging task. Successful recruitment strategies can significantly impact the efficiency and effectiveness of clinical trials, ultimately contributing to bringing new therapies to market faster. To achieve this,
Zephyrm Bioscience has announced its intention to pursue an initial public offering (IPO) on the Hong Kong stock exchange. The biotech company aims to secure significant funding to advance its lead cell therapy candidate, ZH901, into phase 3 clinical trials. ZH901 is targeted at treating both a
The world of medical and pharmaceutical advancements is frequently marked by innovative partnerships that push the boundaries of what is possible in patient care. One such collaboration has recently emerged between Excellos Inc. and Galapagos. These two entities have teamed up to enhance the
The biotech and pharmaceutical industries are highly dynamic fields reliant on constant innovation, robust networking, and strategic investor relations. Professionals in these sectors must attend top biopharma conferences to keep pace with the latest advancements, regulatory trends, and emerging
Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has reached a significant milestone in the development of treatments for post-traumatic stress disorder (PTSD). The company recently announced a Material Transfer Agreement (MTA) with the U.S. Army Medical
BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment